Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index; 21 of the 34 sources its claims cite were checked for support.
Abstract
BACKGROUND: Weight regain after weight loss is a major problem in the treatment of persons with obesity. METHODS: In a randomized, head-to-head, placebo-controlled trial, we enrolled adults with obesity (body-mass index [the weight in kilograms divided by the square of the height in meters], 32 to 43) who did not have diabetes. After an 8-week low-calorie diet, participants were randomly assigned for 1 year to one of four strategies: a moderate-to-vigorous-intensity exercise program plus placebo (exercise group); treatment with liraglutide (3.0 mg per day) plus usual activity (liraglutide group); exercise program plus liraglutide therapy (combination group); or placebo plus usual activity (placebo group). End points with prespecified hypotheses were the change in body weight (primary end point) and the change in body-fat percentage (secondary end point) from randomization to the end of the treatment period in the intention-to-treat population. Prespecified metabolic health-related end points and safety were also assessed. RESULTS: After the 8-week low-calorie diet, 195 participants had a mean decrease in body weight of 13.1 kg. At 1 year, all the active-treatment strategies led to greater weight loss than placebo: difference in the exercise group, -4.1 kg (95% confidence interval [CI], -7.8 to -0.4; P = 0.03); in the liraglutide group, -6.8 kg (95% CI, -10.4 to -3.1; P<0.001); and in the combination group, -9.5 kg (95% CI, -13.1 to -5.9; P<0.001). The combination strategy led to greater weight loss than exercise (difference, -5.4 kg; 95% CI, -9.0 to -1.7; P = 0.004) but not liraglutide (-2.7 kg; 95% CI, -6.3 to 0.8; P = 0.13). The combination strategy decreased body-fat percentage by 3.9 percentage points, which was approximately twice the decrease in the exercise group (-1.7 percentage points; 95% CI, -3.2 to -0.2; P = 0.02) and the liraglutide group (-1.9 percentage points; 95% CI, -3.3 to -0.5; P = 0.009). Only the combination strategy was associated with improvements in the glycated hemoglobin level, insulin sensitivity, and cardiorespiratory fitness. Increased heart rate and cholelithiasis were observed more often in the liraglutide group than in the combination group. CONCLUSIONS: A strategy combining exercise and liraglutide therapy improved healthy weight loss maintenance more than either treatment alone. (Funded by the Novo Nordisk Foundation and others; EudraCT number, 2015-005585-32; ClinicalTrials.gov number, NCT04122716.).
Overview
CoChat Summary
## TL;DR
In this randomized, placebo-controlled trial of adults with obesity who first lost weight on an 8-week low-calorie diet, exercise plus liraglutide maintained weight loss better than either treatment alone. The combination also produced broader metabolic benefits, including improved body-fat percentage, glycated hemoglobin, insulin sensitivity, cardiorespiratory fitness, and physical functioning.
## Key findings
- After the 8-week low-calorie diet, 195 participants had a mean body-weight decrease of 13.1 kg; these participants were randomized to 1 year of treatment.
- At 1 year, compared with placebo, mean weight change differed by -4.1 kg with exercise, -6.8 kg with liraglutide, and -9.5 kg with the combination.
- The combination reduced body-fat percentage by 3.9 percentage points, versus -1.7 percentage points compared with exercise and -1.9 percentage points compared with liraglutide; it was the only strategy associated with improvements in glycated hemoglobin, insulin sensitivity, and cardiorespiratory fitness.
- Mean total weight loss from baseline to end of trial was 15.7% in the combination group, 10.9% with exercise, 13.4% with liraglutide, and 6.7% with placebo.
## Methods
- Investigator-initiated, randomized, head-to-head, placebo-controlled trial at Hvidovre Hospital and the University of Copenhagen; participants were randomized in a 1:1:1:1 ratio after an 8-week 800-kcal/day low-calorie diet.
- Sample: adults 18 to 65 years with obesity (BMI 32 to 43) and no diabetes; 215 started the diet and 195 (those losing at least 5% of baseline weight) were randomized.
- Main analysis used an intention-to-treat repeated-measures linear regression model with time, group, sex, age group, and time-by-group interaction; prespecified supplementary analyses included per-protocol, adjustment for initial weight loss, and multiple imputation.
## Limitations
- The paper states results may not be generalizable to older persons (>65 years), persons with BMI >43, patients with type 2 diabetes, or persons with low adherence to moderate-to-vigorous exercise or limited ability to exercise.
- The authors note that some participants missed the week-52 assessment: 166 of 195 (85%) attended the primary endpoint visit.
- Evident from the text: the trial was conducted in Denmark at two sites and in participants who first achieved at least 5% weight loss on a low-calorie diet, so applicability to broader obesity populations and to people unable to lose weight initially is not directly tested.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
12 Valid · 1 Not valid · 3 Not checked · 76 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“and to increased appetite. 9-11”
What the sources say
- Not checked — no full text of the sourcecites [9] matched to “Successful weight loss maintenance includes long-term increased meal responses of GLP-1 and PYY3-36” (2016) source
- Not checked — no full text of the sourcecites [10] matched to “Long-term persistence of hormonal adaptations to weight loss” (2011) source
- Partly supportedcites [11] matched to “Treatment with a GLP-1 receptor agonist diminishes the decrease in free plasma leptin during maintenance of weight loss” (2015) sourceExperimental — accuracy not yet measured
The Introduction says that increased hunger and reduced satiety after weight loss are among the mechanisms favoring weight regain. It does not say that the regain is rapid, so the claim’s timing is unsupported. (LLM, conf=0.84)
plainstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Diet management programs, including the use of low-calorie mealreplacement products, can sustain low-calorie diet-induced weight loss with a small weight regain. 11,15-17”
What the sources say
- Supportedcites [11] matched to “Treatment with a GLP-1 receptor agonist diminishes the decrease in free plasma leptin during maintenance of weight loss” (2015) source
The Study design describes a dietician-supported maintenance program that allowed low-calorie meal replacements after an initial very low-calorie diet. The Discussion reports that both groups maintained an approximately 12-kg loss over one year, with weight regain of 0.4 kg in the GLP-1RA group and 2.3 kg in the control group. (LLM, conf=0.90)
- Supportedcites [15] matched to “Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial” (2018) source
The Procedures describe a low-energy formula diet followed by food reintroduction and a structured weight-loss maintenance programme. The Results report that participants who engaged lost 14.5 kg during diet replacement, then regained 1.0 kg during food reintroduction and 1.9 kg during weight-loss management. These findings support the claim for this programme in people with type 2 diabetes; page numbers were not supplied. (LLM, conf=0.91)
- Supportedcites [16] matched to “Doctor Referral of Overweight People to Low Energy total diet replacement Treatment (DROPLET): pragmatic randomised controlled trial” (2018) source
The Methods (Interventions; page not provided) describe an 810 kcal/day programme using formula food products, followed by a weight-maintenance phase. The Results (Table 2; page not provided) show that mean weight loss in the treatment group was 15.1 kg at six months and 10.7 kg at 12 months: some weight was regained, but substantial weight loss remained. The Discussion (Implications of this research; page not provided) likewise reports average regain after the programme ended while noting that participants maintained clinically important losses. (LLM, conf=0.87)
- Supportedcites [17] matched to “Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial” (2019) source
The Study design and participants section describes an initial low-calorie formula diet followed by structured weight-maintenance support, including meal replacement when weight was regained. The Results report that the intervention group remained an average of 7.6 kg below baseline at 24 months, despite an average 2.6 kg regain between months 12 and 24. Page numbers are not available in our copy. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Furthermore, lifestyle interventions that encourage increased physical activity concurrent with calorie restriction have been shown to sustain moderate weight loss. 18,19”
What the sources say
- Supportedcites [18] matched to “Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes” (2013) source
The Methods > Interventions passage describes a program combining reduced caloric intake with increased physical activity. The Results > Weight, Waist Circumference and Fitness and Discussion passages report that participants maintained a modest average weight loss of 6.0% at the end of the trial, supporting the claim for overweight or obese adults with type 2 diabetes. (LLM, conf=0.93)
- Not checked — no full text of the sourcecites [19] matched to “Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin” (2002) source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“However, the isolated benefits of exercise to prevent weight regain after weight loss is understudied. 20”
What the sources say
- Partly supportedcites [20] matched to “Is regular exercise an effective strategy for weight loss maintenance?” (2018) sourceExperimental — accuracy not yet measured
Section 2.1 (page unavailable) says randomized trials lack convincing evidence that exercise improves weight-loss maintenance, supporting uncertainty about its benefit. But it also discusses numerous trials and does not say that the isolated benefit of exercise, as distinct from other interventions, has been understudied. (LLM, conf=0.78)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“This is more than the total weight losses of approximately 10% that were obtained with 1-year diet-management programs after an initial low-calorie diet. 11,15,16,29”
What the sources say
- Supportedcites [11] matched to “Treatment with a GLP-1 receptor agonist diminishes the decrease in free plasma leptin during maintenance of weight loss” (2015) source
The Methods describe an initial 8-week very-low-calorie diet followed by a 52-week weight-maintenance program. The Results report an initial 12% weight loss (about 12 kg) and a 2.3 kg regain in the control group after 52 weeks, leaving approximately 10% total weight loss. The cited paper therefore supports the comparison with a roughly 10% loss after a year of diet management. (LLM, conf=0.90)
- Supportedcites [15] matched to “Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial” (2018) source
The Procedures section describes an initial low-energy total diet replacement phase followed by food reintroduction and ongoing weight-loss maintenance. Table S1 (Additional information) reports a 9.9% mean weight loss in the intervention group at 12 months, supporting the cited figure of approximately 10%. The 16% loss with the combination is the citing paper’s comparison, not a result attributed to DiRECT. (LLM, conf=0.92)
- Supportedcites [16] matched to “Doctor Referral of Overweight People to Low Energy total diet replacement Treatment (DROPLET): pragmatic randomised controlled trial” (2018) source
The Methods (Interventions; page unavailable) describe an initial 810 kcal/day total diet replacement followed by food reintroduction and weight-maintenance support. The Results (Primary outcome and baseline characteristics; page unavailable) report a mean loss of 10.7 kg at 12 months from a mean starting weight of 107.9 kg in that group—approximately 10%. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [29] matched to “Effect of intensive lifestyle intervention on bodyweight and glycaemia in early type 2 diabetes (DIADEM-I): an open-label, parallel-group, randomised controlled trial” (2020) source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
42 more claims · 2 with their cited sources checked
Create a free account to see all 92 claims and every source verdict.
- It may state two separate claims as one. 31
- Probably not a substantial claim. 21
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“the overall weight loss was also minimal, since the study was focused on the weight-maintenance period following active weight loss.”
From The Benefits of Exercise Training in Combination With Weight Loss Therapies (2025) · cites this paper as [45]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Only those in the combined therapy group showed sustained improvements in glycated hemoglobin levels, insulin sensitivity, and cardiorespiratory fitness at the 1-year follow-up in the trial.”
From The Benefits of Exercise Training in Combination With Weight Loss Therapies (2025) · cites this paper as [45]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Only those in the combined therapy group showed sustained improvements in glycated hemoglobin levels, insulin sensitivity, and cardiorespiratory fitness at the 1-year follow-up in the trial.”
From The Benefits of Exercise Training in Combination With Weight Loss Therapies (2025) · cites this paper as [45]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“The combination group had a substantial weight reduction of −12.1 kg compared with placebo26, which might in itself increase appetite6.”
From Exploratory analysis of eating-and physical activity-related outcomes from a randomized controlled trial for weight loss maintenance with exercise and liraglutide single or combination treatment (2022) · cites this paper as [26]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Weight loss was maintained in the exercise group with a treatment effect of −5.3 kg compared with placebo26.”
From Exploratory analysis of eating-and physical activity-related outcomes from a randomized controlled trial for weight loss maintenance with exercise and liraglutide single or combination treatment (2022) · cites this paper as [26]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measured
41 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011 · cited 2×
“Diarrhea 38 (19) 4 (8) 7 (15) 13 (27) 14 (29)”
World Health Organization 2020 guidelines on physical activity and sedentary behaviour
Bull, F. C., Al-Ansari, S. S., Biddle, S., Borodulin, K., Buman, M. P., Cardon, G., Carty, C., Chaput, J.-P., Chastin, S., Chou, R., et al. (2020) · British Journal of Sports Medicine · doi:10.1136/bjsports-2020-102955 · Cited by 11,657 · cited 4×
“Abdominal pain 46 (24) 3 (6) 13 (27) 18 (37) 12 (24)”
InfluentialMatsuda, M., & DeFronzo, R. A. (1999) · Diabetes Care · doi:10.2337/diacare.22.9.1462 · Cited by 5,621
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes
The Look AHEAD Research Group (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1212914 · Cited by 2,908
Jensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Donato, K. A., Hu, F. B., Hubbard, V. S., Jakicic, J. M., Kushner, R. F., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437739.71477.ee · Cited by 2,735 · cited 4×
“Adverse event that led to the discontinuation of liraglutide or placebo 5 (3) 0 3 (6) 1 (2) 1 (2)”
BackgroundInfluentialA Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Ross, R., Blair, S. N., Arena, R., Church, T. S., Després, J.-P., Franklin, B. A., Haskell, W. L., Kaminsky, L. A., Levine, B. D., Lavie, C. J., et al. (2016) · Circulation · doi:10.1161/cir.0000000000000461 · Cited by 2,486
Lean, M. E., Leslie, W. S., Barnes, A. C., Brosnahan, N., Thom, G., McCombie, L., Peters, C., Zhyzhneuskaya, S., Al-Mrabeh, A., Hollingsworth, K. G., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)33102-1 · Cited by 2,095 · cited 2×
“Diarrhea 38 (19) 4 (8) 7 (15) 13 (27) 14 (29)”
Changes in Energy Expenditure Resulting from Altered Body Weight
Leibel, R. L., Rosenbaum, M., & Hirsch, J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199503093321001 · Cited by 2,012 · cited 7×
“Serious adverse event† 16 (8) 2 (4) 4 (8) 6 (12) 4 (8)”
Influential
Cited by
Items 201–300 of 526
Meng, Q., Chepurny, O. G., Leech, C. A., Pruekprasert, N., Molnar, M. E., Collier, J. J., Cooney, R. N., & Holz, G. G. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14693 · Cited by 12
“Saline, GTS-21 (4 mg/kg), exendin (9-39) (85 μg/kg), or a combination”
BackgroundMethodInfluentialSchweda, S., Munz, B., Burgstahler, C., Niess, A. M., Roesel, I., Sudeck, G., & Krauß, I. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19159469 · Cited by 13
“Besides physical health outcomes, the positive effects of PA on HRQoL could be demonstrated, even despite other comorbidities [6,16,62,66,68].”
BackgroundCurrent treatment landscape for obesity in Singapore
Lee, P. C., Lim, C. H., Asokkumar, R., & Chua, M. W. J. (2023) · Singapore Medical Journal · doi:10.4103/singaporemedj.smj-2022-216 · Cited by 16
“Most of the management options discussed may be employed synergistically — pharmacotherapy plays an important role as an adjunct to lifestyle intervention in the weight maintenance phase after initial weight loss with lifestyle intervention[87,88] or in settings of inadequate weight loss or weight regain after bariatr…”
BackgroundPharmacologic treatment of obesity in adults: Standards of care in overweight and obesity
C, K. A. C. M. V. R. L. J. K. A. G. A. A. A. B. B. (2025) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2025-005729 · Cited by 36
Brown, A., Mellor, D., Makaronidis, J., Shuttlewood, E., Miras, A. D., & Pournaras, D. J. (2024) · Nutrition Bulletin · doi:10.1111/nbu.12700 · Cited by 9
GLP-1 receptor agonists induce loss of lean mass: So does caloric restriction
Mocciaro, G., Capodici, A., & De Amicis, R. (2025) · BMJ Nutrition, Prevention & Health · doi:10.1136/bmjnph-2025-001206 · Cited by 9
“15 16 An example of successful combina - tion of GLP-1 RA with physical activity for a healthy weight loss in patients with obesity was shown by Lundgren et al , 17 where lean mass loss was minimised by a combined approach.”
Optimizing GLP-1 therapies for obesity and diabetes management
Noronha, J. C., Gaal, L. F. V., Neeland, I. J., Fitch, A., Pfeiffer, A. F. H., Chiavaroli, L., Kendall, C. W. C., & Sievenpiper, J. L. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100222 · Cited by 21
“The intervention involved supervised, group-based aerobic and resistance training totaling more than 150 minutes per week at 60 – 85 % of maximum heart rate [6].”
InfluentialChrysavgis, L., Mourelatou, N. G., Koloutsou, M. E., Rozani, S., & Cholongitas, Ε. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262412130 · Cited by 16
Lifestyle management approaches for obesity
Landry, M. J., & Bagha, Z. M. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.08.022 · Cited by 15
Holt, R., Holt, J., Jorsal, M. J., Sandsdal, R. M., Jensen, S. B. K., Byberg, S., Juhl, C. R., Lundgren, J. R., Janus, C., Stallknecht, B. M., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae775 · Cited by 13
Self-citationGarvey, W. T., Cheng, M., Ramasamy, A., Smolarz, B. G., Park, S., Kumar, N., Kim, N., DerSarkissian, M., Bhak, R. H., Duh, M. S., et al. (2023) · Population Health Management · doi:10.1089/pop.2022.0227 · Cited by 9
“…of its effectiveness in real-world cohorts in Canada 32 and Belgium 31 and clinical trial data showing that liraglutide combined with exercise 40 or intensive behavioral therapy 41,42 significantly improved cardiometabolic indices and resulted in significant weight loss in adults with obesity.”
Abouelgreed, T. A., Elatreisy, A., El‐Sherbiny, A. F., Abdelaal, M. A., Saafan, T., Shalkamy, O., Farag, H. I., Ghoneimy, O. M., El-Dydamony, E. M., Ibrahim, E. H., et al. (2023) · Basic and Clinical Andrology · doi:10.1186/s12610-023-00191-1 · Cited by 11
“It could be augmented by regular physical exercise as the latter was reported to improve cardiorespiratory fitness, emotional well-being, level of glycated hemoglobin, and insulin sensitivity [31].”
BackgroundContemporary Treatments for Obesity: Physical Activity in the Context of Antiobesity Medications
Jakicic, J. M., Rogers, R. J., & Apovian, C. M. (2024) · Translational Journal of the American College of Sports Medicine · doi:10.1249/tjx.0000000000000253 · Cited by 10
Jensen, S. B. K., Fiorenza, M., Juhl, C. R., Sandsdal, R. M., Jensen, E., Seier, S. S., Janus, C., Jørgensen, J. R., Blond, M. B., Holst, J. J., et al. (2026) · Sports Medicine · doi:10.1007/s40279-025-02386-0 · Cited by 9
“The sample size was calculated based on the primary end-point, a change in body weight [29].”
InfluentialSelf-citationThe Benefits of Exercise Training in Combination With Weight Loss Therapies
Jiang, B. C., & Villareal, D. T. (2025) · Diabetes · doi:10.2337/dbi25-0001 · Cited by 9
Obesity is South Africa’s new HIV epidemic
Chandiwana, N. C., Venter, F., Manne‐Goehler, J., Wade, A. N., le Roux, C. W., Mbalati, N., Grimbeek, A., Kruger, P., Montsho, E., Zimela, Z., et al. (2024) · South African Medical Journal · doi:10.7196/samj.2024.v114i3.1927 · Cited by 11
Body mass index is a barrier to obesity treatment
Chin, G. C., Potter, A. W., & Friedl, K. E. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1444568 · Cited by 13
Zupec, J. F., Munger, R., Scaletta, A., & Quinn, D. H. (2025) · Nutrition in Clinical Practice · doi:10.1002/ncp.11279 · Cited by 9
Kurevija, T., Šojat, D., Bilić-Čurčić, I., Canecki-Varžić, S., & Majnarić, L. T. (2025) · BMC Family Practice · doi:10.1186/s12875-025-02837-7 · Cited by 9
“Conversely, GLP-1 RAs and the newer insulin secretion-stimulating medication tirzepatide are preferred for weight loss in obese individuals with T2D [13, 14].”
Steenackers, N., Toumassian, J., Deleus, E., Mertens, A. C., Lannoo, M., Pazmiño, S., van Laar, A. D. E., der Schueren, B. V., & Vangoitsenhoven, R. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1569468 · Cited by 21
Glycemic therapies and the risk of gastrointestinal adverse events in veterans with type 2 diabetes
Sarwal, A., Singh, R., Wei, G., Shen, J., Nevers, M. R., Hartsell, S. E., Derington, C. G., Takyi, A., Chakravartula, A. R., Katkam, N., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16642 · Cited by 8
“13 However, in the current analysis that compared GLP-1RA to insulin glargine or SGLT2i, there was no evidence that GLP-1RA had a higher risk of gallstones or cholecystitis.”
Sarcopenia and sarcopenic obesity in cardiovascular disease: a comprehensive review
Tan, L. F., Sia, C., & Merchant, R. A. (2025) · Singapore Medical Journal · doi:10.4103/singaporemedj.smj-2024-233 · Cited by 10
Antiobesity Medications for Older Adults—the New, the Good, the Bad, and the Unknown
Pendrey, A., & Sevilla‐Martir, J. (2025) · Obesity · doi:10.1002/oby.70029 · Cited by 11
“These interventions are thoroughly described and reviewed elsewhere [81, 82].”
Minnetti, M., Barazzoni, R., Batsis, J. A., Busetto, L., Yumuk, V., Poggiogalle, E., Weijs, P. J. M., & Donini, L. M. (2025) · Obesity Facts · doi:10.1159/000548370 · Cited by 15
“…on individualized planning by exercise physiologists, included supervised high-intensity interval cycling, circuit training, and independent moderate-to-vigorous activities, emphasizing the critical role of structured physical exercise in sustaining weight loss and improving health outcomes [91].”
Emerging Medical Therapies for the Treatment of Obesity in Women with Cardiovascular Diseases
Behrooz, L., Lenneman, C. G., & Hamburg, N. M. (2023) · Current Cardiology Reports · doi:10.1007/s11886-023-01961-z · Cited by 9
“The combination of liraglutide with an exercise intervention had enhanced efficacy for maintaining weight loss [118].”
BackgroundMatias, I., Lehmann, E., Zizzari, P., Byberg, S., Cota, D., Torekov, S. S., & Quarta, C. (2023) · Journal of Endocrinological Investigation · doi:10.1007/s40618-023-02228-8 · Cited by 7
“…(GLP-1RAs) can significantly improve glycaemia, dyslipidemia and body weight (BW) control in patients with type 2 diabetes (T2D) and obesity [1, 2], but the exceptional benefits of these molecules are hampered by subject-specific heterogeneity in the magnitude of pharmacological response [3, 4].”
Self-citationCai, J., Yue, J., Lu, N., Li, S., Zheng, J., Huang, R., Jiang, Y., Shan, C., Liu, W., Ma, J., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13020483 · Cited by 9
“Interventions of weight loss have consistently been linked to reductions in cardiovascular risk factors, such as improved glycemic control, insulin sensitivity, and cardiorespiratory fitness [64,65].”
BackgroundDietary and pharmacological energy restriction and exercise for healthspan extension
Cagigas, M. L., Ciutiis, I. D., Masedunskas, A., & Fontana, L. (2025) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2025.04.001 · Cited by 15
(2021) · The Nurse Practitioner · doi:10.1097/01.npr.0000769780.52757.f4 · Cited by 8
d’Aquino, A. I., Maikawa, C. L., Nguyen, L. T., Lu, K., Hall, I. A., Jons, C. K., Kasse, C. M., Yan, J., Prossnitz, A. N., Chang, E., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.01.28.526057 · Cited by 8
“Such regimens include continuous subcutaneous infusion of GLP-1 (12-14), and once- or twicedaily or weekly injections of GLP-1 analogues with extended plasma stability (14, 15).”
BackgroundFocus on Glucagon-like Peptide-1 Target: Drugs Approved or Designed to Treat Obesity
Zhang, J., Wei, J., Lai, W., Sun, J., Bai, Y., Cao, H., Guo, J., & Su, Z. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26041651 · Cited by 9
Alfehaid, L., Yami, M. S. A., Almohareb, S. N., Alshaya, O. A., & Almutairi, A. R. (2025) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2025.2465870 · Cited by 13
Rodriguez, N. S., & Hartmann, P. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100058 · Cited by 13
Monitoring Sarcopenia With Incretin Receptor Activator Treatment
Bloomgarden, Z. T. (2025) · Journal of Diabetes · doi:10.1111/1753-0407.70117 · Cited by 10
“…can be utilized in patients treated with these agents, including incretin receptor activator dose reduction in appropriate patients, routine patient enrollment in structured exercise programs [36, 37], and ultimately the use of specific agents currently in development to prevent sarcopenia [38].”
Holt, J., Sandsdal, R. M., Byberg, S., Janus, C., Juhl, C. R., Jørgensen, J. R., Hartmann, B., Stallknecht, B. M., Holst, J. J., Madsbad, S., et al. (2025) · Obesity · doi:10.1002/oby.70043 · Cited by 8
“An exercise program can maintain weight loss for up to 2 years [6, 7], and successful weight loss maintenance is associated with higher levels of physical activity [13].”
InfluentialSelf-citationPharmacologic Treatment of Obesity in Adults: Standards of Care in Overweight and Obesity
Gudzune, K. A., Apovian, C. M., Aroda, V. R., Aronne, L. J., Balapattabi, K., Bennett, A. K., ChallaSivaKanaka, S., ElSayed, N. A., Fitch, A., Fitzpatrick, S. L., et al. (2026) · Diabetes Obesity and Cardiometabolic CARE · doi:10.2337/doci25-0008 · Cited by 27
Long, X., Liu, H., Xiong, W., Li, W., He, H., Fu, T., Li, X., Chen, C., Zhang, L., & Liu, Y. (2023) · Gynecological Endocrinology · doi:10.1080/09513590.2023.2223648 · Cited by 7
“As an anti-diabetic therapy is approved at doses up to 1.8 mg [20], while higher doses are required for weight loss in many countries [19, 21].”
BackgroundInfluentialKCNQ5 Controls Perivascular Adipose Tissue–Mediated Vasodilation
Tsvetkov, D., Schleifenbaum, J., Wang, Y., Kaßmann, M., Polovitskaya, M. M., Ali, M., Schütze, S., Rothe, M., Luft, F. C., Jentsch, T. J., et al. (2023) · Hypertension · doi:10.1161/hypertensionaha.123.21834 · Cited by 12
“In addition to drug therapy, for example, with GLP-1 (glucagon-like peptide-1) agonists or agents targeting inflammatory interleukins, 49–52 addressing oxylipins and KCNQ5 channels may improve outcomes further.”
BackgroundKurevija, T., Šojat, D., Bosnić, Z., Mujaj, B., Canecki-Varžić, S., & Majnarić, L. T. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13061617 · Cited by 9
“In addition, an increased CV risk can be ameliorated through the potent effect of these drugs—in particular, GLP-1ra and the emerging insulin secretion stimulating drug tirzepatide—on body weight reduction [50,51].”
BackgroundExercise in the maintenance of weight loss: health benefits beyond lost weight on the scale
D’Souza, A. C., Lau, K. J., & Phillips, S. M. (2021) · British Journal of Sports Medicine · doi:10.1136/bjsports-2021-104754 · Cited by 12
Kolli, R. T., Aoutla, S., Jyothi, N., Mohamed Kalifa, M. R. H., Raju, A., & Cheenikkal Muralidharan, K. (2025) · Cureus · doi:10.7759/cureus.94926 · Cited by 7
Brun, J.-F., Myzia, J., Varlet-Marie, E., Mercier, J., & Raynaud de Mauverger, E. (2022) · Science & Sports · doi:10.1016/j.scispo.2022.03.002 · Cited by 6
Modern and Non-Invasive Methods of Fat Removal
Piłat, P., Szpila, G., Stojko, M., Nocoń, J., Smolarczyk, J., Żmudka, K. J., Moll, M., & Hawranek, M. (2023) · Medicina · doi:10.3390/medicina59081378 · Cited by 8
“At the endpoint, participants’ body weight was lowered by an average of 12% [48].”
BackgroundThe Enteric Neuronal Circuitry: A Key Ignored Player in Nutrient Sensing Along the Gut–Brain Axis
Nikolla, E., Grandberry, A., Jamerson, D., Flynn, C. R., & Sundaresan, S. (2025) · The FASEB Journal · doi:10.1096/fj.202500220rr · Cited by 7
Obesity Medication Treatment Perspectives Among People with Overweight or Obesity
Ostrominski, J. W., Chhibber, A., Kuti, E. L., Clark, B. J., & Donato, B. M. K. (2025) · Patient Preference and Adherence · doi:10.2147/ppa.s555622 · Cited by 8
“62 Additionally, fewer than half of PwO discussed treatment duration and most expected therapy to last less than 2 years despite evidence from clinical trials supporting longitudinal use to maintain treatment benefits, 23,26,27 including maintenance of disease control and prevention of recurrence.”
Basolo, A., Paolucci, G., Piaggi, P., Angeli, V., Genzano, S. B., Fierabracci, P., Vignali, E., Bologna, C., Salvetti, G., Chiovato, L., et al. (2025) · Journal of Endocrinological Investigation · doi:10.1007/s40618-025-02717-y · Cited by 10
Jansson, A. K., Gómez‐Martín, M., Hedin, L. E., Clarke, E. D., Cross, V., Stanford, J., Taylor, R., Bogl, L. H., de Vlieger, N., Koochek, A., et al. (2026) · Obesity Reviews · doi:10.1111/obr.70077 · Cited by 13
Exercise as a therapeutic intervention for long-lasting and chronic diseases
Febbraio, M. A., & Pedersen, B. K. (2026) · Cell Metabolism · doi:10.1016/j.cmet.2026.02.017 · Cited by 12
2026 ESC Guidelines on cardiac rehabilitation
Bäck, M., Wilhelm, M., Marcin, T., Machado, F. V. C., Sandberg, A., Buccheri, S., Conde, A. C., Czapla, M., Rosa, S. D., Gibson, I., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag099 · Cited by 44
Hu, Y., Huang, H., Jiang, Y., Zhang, J., Zhang, Y., Tian, Y., & Zhang, Q. (2024) · Aging · doi:10.18632/aging.205558 · Cited by 6
Ghoreishy, S. M., Noormohammadi, M., Zeraattalab-Motlagh, S., Shoaibinobarian, N., Rashedi, M. H., Movahed, S., Hemmati, A., Nazarian, A., Fernandez, M. L., & Shidfar, F. (2024) · Nutrition Reviews · doi:10.1093/nutrit/nuae128 · Cited by 7
NMDA Receptors in POMC Neurons Connect Exercise With Insulin Sensitivity
Portillo, B., Hwang, E., Ajwani, J., Grose, K. C., Lieu, L., Wallace, B., Kabahizi, A., Elmquist, J. K., & Williams, K. W. (2024) · Diabetes · doi:10.2337/dbi24-0002 · Cited by 6
Wen, J., How-Volkman, C., Truong, A., Nadora, D., Bernstein, E. M., Akhtar, M., Puglisi, J. L., & Frezza, E. E. (2024) · Cureus · doi:10.7759/cureus.75304 · Cited by 12
“Additionally, these weight loss effects are augmented by delayed gastric emptying and stimulation of central receptors that control appetite suppression and energy expenditure [3].”
Efeitos adversos da semaglutida comparada à liraglutida: uma revisão integrativa de literatura
de Moraes, A. L. S. M., Vilela, B. S., Souza, B. C., Falleiros, I. D. F. I., Monteiro, I. D. L. P., & Ribeiro, J. S. O. (2022) · Research Society and Development · doi:10.33448/rsd-v11i10.33181 · Cited by 32
The Healthiest Diet for You: Scientific Aspects
Simopoulos, A. P. (2022) · MDPI eBooks · doi:10.3390/books978-3-0365-2734-5 · Cited by 9
The Healthiest Diet for You: Scientific Aspects
Simopoulos, A. P. (2022) · MDPI eBooks · doi:10.3390/books978-3-0365-2734-5-1 · Cited by 7
(2023) · Nature Medicine · doi:10.1038/s41591-023-02614-y · Cited by 7
Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H. H., Müller‐Wieland, D., Nauck, M. A., Wiesner, T., & Siegel, E. G. (2024) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-2166-6755 · Cited by 7
“The combination therapy also resulted in a 3.9 % reduction in body fat mass, which was approximately 2-fold higher than in the physical activity group ( − 1.7 %; 95 % CI − 3.2 to − 0.2; p = 0.02) and in the liraglutide group alone ( − 1.9 %; 95 % CI − 3.3 to − 0.5; p = 0.009) [159].”
InfluentialDoes physical activity cause weight loss?
Robinson, E., & Stensel, D. J. (2022) · International Journal of Obesity · doi:10.1038/s41366-022-01247-4 · Cited by 10
“[11] found that combining liraglutide therapy and physical activity improved weight loss maintenance significantly more so than liraglutide therapy alone, but further inquiry will be needed.”
BackgroundZoomForward2022: European Congress on Obesity
Jørgensen, R. M., Bøttger, B., Vestergaard, E. T., Kremke, B., Bahnsen, R. F., Nielsen, B. W., & Bruun, J. M. (2022) · Obesity Facts · doi:10.1159/000524469 · Cited by 8
Bariatric outcomes of high BMI patients with preoperative anti-obesity medications
Obermark, A. D., Seo, D. Y., Bernazard, A., Richards, J. R., Phillippe, S., Khorgami, Z., & Chow, G. S. (2025) · Surgical Endoscopy · doi:10.1007/s00464-025-11851-w · Cited by 5
“These results support other research studies highlighting the use of GLP-1 agonists and lifestyle changes, resulting in significant weight loss [10, 14, 15].”
Evolution of multidisciplinary obesity treatments: past, present, and future role of nutrition
Heymsfield, S. B., Atherton, P. J., Christensen, S. M., Tewksbury, C. M., Velazquez, A., Walter, J., & Blaak, E. E. (2025) · Obesity · doi:10.1002/oby.24340 · Cited by 7
“One randomized, placebo-controlled study found that liraglutide in combination with a moderate-to-vigorous exercise program was more effective in maintaining healthy weight loss compared with either intervention alone [ 43].”
Cerchi, E., Santo, P. A. D. E., de Oliveira, M. C., Janovsky, C. C. P. S., & Halpern, B. (2025) · International Journal of Obesity · doi:10.1038/s41366-025-01920-4 · Cited by 9
Al-Awadi, A. A., Alroudhan, D., Alsaeed, D., Almarshad, B. W., Alshehabi, D. H., Al‐Lahou, B., Mashankar, A., Al‐Ozairi, E., & Gray, S. (2026) · BMJ Open · doi:10.1136/bmjopen-2026-116911 · Cited by 16
“27 Furthermore, prior interventions have relied on supervised gym-based programmes, limiting scalability.”
The Conundrum of Exercise for Weight Management in the GLP-1 Receptor Agonist Era
Lieberman, D. E., Aslan, D. H., & Heymsfield, S. B. (2026) · JAMA · doi:10.1001/jama.2026.5537 · Cited by 10
Newsom, S. A., & Robinson, M. M. (2024) · Physiological Reports · doi:10.14814/phy2.16093 · Cited by 5
“Lundgren et al. studied liraglutide and exercise in patients who had already lost over 5% of body weight ( ~ 13 kg) and found that combining exercise with drug treatment promoted additional loss of body weight, mostly fat mass, of ~ 5.4 kg more than exercise alone (Lundgren et al., 2021).”
BackgroundInfluentialWhy you should not skip tailored exercise interventions when using incretin mimetics for weight loss
Gross, K., & Brinkmann, C. K. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1449653 · Cited by 7
Glucagon-Like Peptide-1 Agonist Use in Adults With Congenital Heart Disease
Thapa, R., Lara-Breitinger, K. M., López-Jiménez, F. A., Shama, N., Egbe, A. C., Miranda, W. R., Connolly, H. M., Jain, C. C., Jokhadar, M., Kosec, A. M., et al. (2025) · JACC Advances · doi:10.1016/j.jacadv.2025.101674 · Cited by 6
Espinola, O. P., Tobias, D. K., & Manson, J. E. (2025) · American Journal of Lifestyle Medicine · doi:10.1177/15598276251372427 · Cited by 10
“68 Indeed, even in the setting of effective T2D and weight loss medications, concomitant lifestyle interventions remain highly relevant and provide additional broad-spectrum bene fi ts.”
Recommendations for the prevention and management of obesity in the Iraqi population
Nwayyir, H. A., Mutasher, E. M., Alabid, O. M., Jabbar, M. A., Al-Kawaz, W. H. A., Alidrisi, H. A., Alabbood, M., Chabek, M., Alzubaidi, M. A., Alkhazrajy, L. A., et al. (2023) · Postgraduate Medicine · doi:10.1080/00325481.2023.2172914 · Cited by 9
“liraglutide) with exercise leads to better weight loss maintenance[96].”
BackgroundShao, L.-J.-Z., Liu, Y., Hao, J., et al. (2023) · Drug Design Development and Therapy · doi:10.2147/dddt.s413535 · Cited by 5
“4 However, for patients with severe obesity, laparoscopy bariatric surgery is still considered the golden standard in metabolic surgery.”
BackgroundHathorn, B., Haykowsky, M. J., Almandoz, J. P., Pandey, A., Sarma, S., Hearon, C. M., Babb, T. G., Balmain, B. N., Fu, Q., Zaha, V. G., et al. (2025) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2025.03.015 · Cited by 9
Castro, N. I. Q., Almeida, M., Orbea, A. F., Andrade, D. N., Carrera, J. F., Vargas, F. Y., & Carrasco, M. L. (2025) · Cureus · doi:10.7759/cureus.82479 · Cited by 6
Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined
Barreto, P. D. S., & Rolland, Y. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2109509 · Cited by 5
Glucagon-like peptide-1 receptor agonists: the key to healthy weight loss maintenance?
Iepsen, E. W., & Torekov, S. S. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab249 · Cited by 5
Self-citationXu, W.-L., Li, J., Ji, C., Fang, D., Yao, L., Xu, N., & Wei, Y. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1145079 · Cited by 6
“In clinical practice, weight control is often combined with exercise and drugs to reduce weight (Bray et al., 2016; Lundgren et al., 2021).”
BackgroundKoriath, C., & Perneczky, R. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251338467 · Cited by 7
Srivastava, G., Campbell, S. L., Hill, C. R., Stanley, T. L., Lawson, E. A., Apovian, C. M., Almandoz, J. P., Leggio, L., Lakdawalla, D. N., Dar, M., et al. (2025) · The American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2025.06.015 · Cited by 5
“Work by Lundgren et al. [114], published in the New England Journal of Medicine in 2021, investigates strategies for maintaining weight loss in individuals with obesity.”
The Goldilocks for chronic weight management—Balancing quantity with quality of weight loss
Henriksen, K., Chakravarthy, M. V., Bager, C. L., Larsen, A. T., Mohamed, K. E., & Karsdal, M. A. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16379 · Cited by 4
“112 In a study addressing different approaches to the prevention of weight regain following a very low-calorie diet (VLCD) induced weight loss, it was demonstrated that for total weight loss a combination of exercise and liraglutide was superior.”
Body composition during major incretin-based weight loss
Dirksen, C., & Madsbad, S. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00122-6 · Cited by 5
Self-citationExercise pills for cardiometabolic health cannot mimic the exercise milieu
Plaza‐Florido, A., Lindholm, M. E., Carrera‐Bastos, P., Santos‐Lozano, A., Valenzuela, P. L., Fiuza‐Luces, C., Radom‐Aizik, S., & Lucía, A. (2025) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2025.07.005 · Cited by 7
Sun, Y., Liu, Y., Ye, W., Lebaka, V. R., Venkatrayulu, C., Li, W., & Korivi, M. (2025) · International Journal of Behavioral Nutrition and Physical Activity · doi:10.1186/s12966-025-01812-w · Cited by 6
“Changes in anthropometrics, particularly weight gain is associated with increased risk of obesity, type 2 diabetes, and all-cause mortality [56], while weight loss is associated with reduced diabetic complications and improved physical functioning [57, 58].”
Barazzoni, R., Monami, M., Buscemi, S., Busetto, L., Luca, M. D., Navarra, G., Ragghianti, B., Silverii, G. A., Belluzzi, A., Mannucci, E., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70204 · Cited by 7
Box, M. W., Puga, T. B., Werthmann, N. J., Jen, A., Liu, Y., & Riehl, J. T. (2025) · The Knee · doi:10.1016/j.knee.2025.10.026 · Cited by 4
Luca, M. D., COHEN, R. V., Belluzzi, A., Navarra, G., Lorenzo, N. D., Petry, T. B. Z., Sbraccia, P., Busetto, L., Buscemi, S., Barazzoni, R., et al. (2026) · Obesity · doi:10.1002/oby.70083 · Cited by 5
Garg, S. K., Aktürk, H. K., Garg, S., Beck, R. W., Bellini, N. J., Bjornstad, P., Carlson, A. L., Carroll, J., Close, K., Block, C., et al. (2026) · Diabetes Technology & Therapeutics · doi:10.1177/15209156261449879 · Cited by 8
Jimenez, L., Múñoz, Ó., Alfonso, D., & Medina, A. M. G. (2026) · International Journal of Obesity · doi:10.1038/s41366-026-02118-y · Cited by 15
“This fi nding underscores the need for complementary strategies, such as resistance exercise and adequate protein intake during GLP1-RA therapy [23].”
GLP-1 and GIP: Magic bullet for musculoskeletal diseases?
Fang, Q., Gan, L., Liu, P., Ding, P., & Gao, Y. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.08.046 · Cited by 6
Liraglutide for adults living with obesity
Meza, N., Bracchiglione, J., Liquitay, C. M. E., Madrid, E., Varela, L. B., Guo, Y., Urrútia, G., er, S. F. S., Tiller, S., Shokraee, K., et al. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd016017 · Cited by 16
Wretlind, A., Zobel, E. H., de Zawadzki, A., Ripa, R. S., Curovic, V. R., von Scholten, B. J., Mattila, I. M., Hansen, T. W., Kjær, A., Vestergaard, H., et al. (2022) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2022.856485 · Cited by 4
Li, Q., Yang, Q., Han, J. D. J., Xiaohan, L. I. U., Fu, J., & Yin, J. (2022) · Chinese Journal of Natural Medicines · doi:10.1016/s1875-5364(22)60196-1 · Cited by 4
AMPK-Mediated Multi-Organ Protective Effects of GLP-1 Receptor Agonists
Wang, X., & Wang, L. (2025) · Health and Metabolism · doi:10.53941/hm.2025.100004 · Cited by 7
“In a study, female C57BL/6J mice were subcutaneously injected with dehydroepiandrosterone for 21 days to establish a PCOS model.”
Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H. H., Müller‐Wieland, D., Nauck, M. A., Wiesner, T., & Siegel, E. G. (2022) · Die Diabetologie · doi:10.1007/s11428-022-00921-5 · Cited by 8
“2-mal höher war als in der körperlicher Aktivitätsgruppe (–1,7%; 95%-KI: –3,2––0,2; p= 0,02) und in der Liraglutidgruppe allein (–1,9%; 95%-KI: –3,3––0,5;p=0,009, [211]).”
A Study on Weight Loss Cause as per the Side Effect of Liraglutide
Yu, J. S., Lee, J., Lee, S., Cho, J., & Kim, H. (2022) · Cardiovascular Therapeutics · doi:10.1155/2022/5201684 · Cited by 9
“43 kg every year; however, it is reported that the weight loss effect is significant even when the weight is recovered [1, 6, 13, 17].”
Backgroundde Freitas, G. C. P. L., Vasconcelos, M. C. D. H. V., Bisneta, A. I. S., Parra, R. L. O., Pereira, M. E. B., Negreiros, M. E. L., Toledo, M. B., Alves, G. C., & Sobrinho, F. E. R. A. (2023) · Research Society and Development · doi:10.33448/rsd-v12i4.40955 · Cited by 9
Weight Loss That Lasts: Reviewing the Long-Term Impact of GLP-1 Receptor Agonists
Shah, M. Y., Mohammad, A., Samejo, R. B. A., Rana, S., Singla, S., Aurangzeb, R. I., Tariq, M. M., Zamir, M. H., Farooq, U., Aurangzeb, R. F., et al. (2025) · Cureus · doi:10.7759/cureus.88334 · Cited by 12
“Liraglutide 3.0 mg/day, especially when combined with exercise, led to greater reductions in fat mass and improved metabolic health over 52 weeks [11,14].”
InfluentialLarsen, A. T., Melander, S. A., Mohamed, K. E., Petersen, E. A., Benmarce, M., Karsdal, M. A., & Henriksen, K. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118388 · Cited by 3
Berković, M. C., Ružić, L., Cigrovski, V., & Strollo, F. (2025) · World Journal of Diabetes · doi:10.4239/wjd.v16.i9.109123 · Cited by 10
Valério, C. M., Saraiva, J. F. K., Valente, F., van de Sande‐Lee, S., Rocha, V. Z., Rached, F. H., Drager, L. F., Halpern, B., Júnior, W. S. D. S., Trujilho, F. R., et al. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01954-8 · Cited by 11
The Bounce-back Effect: What Happens After Cessation of Low-dose Semaglutide in People With HIV
Erlandson, K. M., Kitch, D. W., Kantor, A., Belaunzarán-Zamudio, P. F., Brown, T. T., Fichtenbaum, C. J., Heath, S. L., Sattler, F. R., & Lake, J. E. (2025) · Clinical Infectious Diseases · doi:10.1093/cid/ciaf652 · Cited by 7
“Incorporating lifestyle change is essential in ongoing weight maintenance, including sustainable physical activity and healthy nutrition [11, 12], and have been shown to limit weight regain either alone or in combination with GLP-1 RA therapy [13].”
Metadata
- Authors
- Lundgren, J. R., Janus, C., Jensen, S. B. K., Juhl, C. R., Olsen, L. M., Christensen, R. M., Svane, M. S., Bandholm, T., Bojsen-Møller, K. N., Blond, M. B., Jensen, J.-E. B., Stallknecht, B. M., Holst, J. J., Madsbad, S., & Torekov, S. S.
- Affiliations
- University of Copenhagen (DK)
- From the Department of Biomedical Sciences (J.R.L., C.J., S.B.K.J., C.R.J., L.M.O., R.M.C., M.B.B., B.M.S., J.J.H., S.S.T.), the Novo Nordisk Foundation Center for Basic Metabolic Research (J.R.L., C.J., S.B.K.J., C.R.J., L.M.O., R.M.C., J.J.H., S.S.T.), the Department of Clinical Medicine (T.B., J.-E.B.J.), University of Copenhagen, and the Departments of Endocrinology (M.S.S., K.N.B.-M., J.-E.B.J., S.M.) and Clinical Research (T.B.), Copenhagen University Hospital–Amager and Hvidovre, Copenhagen, and the Steno Diabetes Center Copenhagen, Gentofte (M.B.B.) — all in Denmark.
- Amager Hospital (DK)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-05-06
- Volume
- 384
- Issue
- 18
- Pages
- 1719-1730
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3158123746
- Cited by
- 536
- References
- 35
- Citations by year
- 2026: 140 · 2025: 137 · 2024: 86 · 2023: 78 · 2022: 71 · 2021: 23
- FWCI
- 37.66
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, other-oa)
- Funders
- Helse Fonden
- Det Sundhedsvidenskabelige Fakultet, Københavns Universitet
- Danish Diabetes Academy
- Novo Nordisk Fonden (NNF15CC0018486, NNF16OC0019968)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Obesity, Physical Activity, Diet
- Keywords
- obesity, weight loss maintenance, weight regain, liraglutide, physical activity, hypocaloric diet, body fat percentage, GLP-1 receptor agonists, combination therapy, metabolic health
- MeSH terms
- Liraglutide, Adipose Tissue, Adult, Combined Modality Therapy, Exercise Therapy, Female, Humans, Male, Middle Aged, Obesity, Weight Loss, Anti-Obesity Agents, Caloric Restriction, Body Size
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.